Quetiapine-induced Stevens–Johnson syndrome: A rare case report

Abstract

Quetiapine, a second-generation antipsychotic drug, commonly has very less propensity of extrapyramidal symptoms and has an added advantage of less risk of serum prolactin, weight gain, or metabolic syndrome than other second-generation antipsychotics. Stevens–Johnson syndrome (SJS) is more commonly reported with anticonvulsant use, and less commonly with antipsychotics. To our knowledge, there is very few evidence of quetiapine-induced SJS in literature. Hence, we present a case of SJS in a patient who was on quetiapine.